Table 1.
Characteristics of the peanut allergic discovery cohort (n=21) and replication cohort (n=19)
| Discovery Cohort (n=21) | Replication Cohort (n=19) | P-value* | |
|---|---|---|---|
| Sex- Female | 7 (33.3%) | 7 (36.8%) | 0.99 |
| Age (years) | 11.0 (5.0) | 12.0 (4.0) | 0.33 |
| Parental allergy | 21 (100.0%) | 16 (84.2%) | 0.10 |
| Peanut sIgE (kUa/L) | 87.4 (140.5) | 68.0 (82.8) | 0.50 |
| Peanut skin prick test (mm) | 13.0 (11.0) | 12.0 (6.0) | 0.32 |
| Cumulative dose at first objective symptom (g peanut protein) | 0.044 (0.14) | 0.014 (0.44) | 0.59 |
| Cumulative successfully consumed dose (g peanut protein) | 0.144 (0.40) | 0.144 (0.48) | 0.80 |
| Reaction severity score | 21.0 (21.0) | 12.0 (13.5) | 0.02 |
| Symptoms experienced during peanut challenge | |||
| Distress | 14 (66.7%) | 13 (68.4%) | 0.99 |
| Throat tightness | 6 (28.6%) | 9 (47.4%) | 0.33 |
| Rhinorrhea | 2 (9.5%) | 3 (15.8%) | 0.65 |
| Rash | 4 (19.0%) | 1 (5.3%) | 0.35 |
| Rubbing of eyes, nose or scratching | 3 (14.3%) | 2 (10.5%) | 0.98 |
| Urticaria: 1–2 lesions | 6 (28.6%) | 3 (15.8%) | 0.46 |
| Urticaria: >3 lesions | 5 (23.8%) | 2 (10.5%) | 0.41 |
| Angioedema | 9 (42.9%) | 4 (21.1%) | 0.19 |
| Vomit: single | 2 (9.5%) | 2 (10.5%) | 0.99 |
| Vomit: multiple times | 0 (0.0%) | 1 (5.3%) | 0.48 |
| Abdominal pain: severe | 5 (23.8%) | 2 (10.5%) | 0.41 |
| Diarrhea | 1 (4.8%) | 0 (0.0%) | 0.99 |
| Wheezing | 1 (4.8%) | 0 (0.0%) | 0.99 |
| Stridor | 0 (0.0%) | 1 (5.3%) | 0.48 |
| Hypotension | 0 (0.0%) | 0 (0.0%) | 1.00 |
Number (percent) or Median (IQR) are shown.
*
Fisher’s Exact test for categorical variables and Wilcoxon signed rank test for continuous variables.